Skip to main content
. 2013 Apr 10;8(4):e60057. doi: 10.1371/journal.pone.0060057

Table 5. Complications of gangrene, osteomyelitis, and bacteremia/endocarditis/septicemia/sepsis by diabetes status, major initial clinical diagnosis, and setting from 2005 through 2010.

Type of SSTI-associated complicationa
Gangrene Osteomyelitis Bacteremia/Endocarditis/Septicemia/Sepsis
In Diabetic Individuals In Non-diabetic Individuals Differ-ence In Diabetic Individuals In Non-diabetic Individuals Differ-ence In Diabetic Individuals In Non-diabetic Individuals Differ-ence
Initial Diagnosis Setting and group of SSTIs N (%) N (%) p-value N (%) N (%) p-value N (%) N (%) p-value
Initially Diagnosed in Ambulatory Settings
Abscess/Cellulitis 551 (0.43%) 432 (0.04%) <.01 1,783 (1.38%) 3,995 (0.35%) <.01 1,050 (0.81%) 3,161 (0.28%) <.01
Decubitus Ulcer 1,239 (7.76%) 372 (2.11%) <.01 4,014 (25.13%) 1,522 (8.62%) <.01 1,273 (7.97%) 735 (4.16%) <.01
Surgical site infection & Device or Graft 33 (0.46%) 52 (0.14%) <.01 241 (3.40%) 972 (2.60%) <.01 525 (7.40%) 909 (2.43%) <.01
Folliculitis, Impetigo, Furuncle, Mastitis & Other SSTIs 113 (0.25%) 159 (0.02%) <.01 344 (0.77%) 1,005 (0.14%) <.01 269 (0.60%) 1,309 (0.18%) <.01
All SSTIs in subgroup 1,936 (0.98%) 1,015 (0.05%) <.01 6,382 (3.25%) 7,494 (0.39%) <.01 3,117 (1.59%) 6,114 (0.32%) <.01
Initially Diagnosed in Inpatient Setting
Abscess/Cellulitis 669 (5.29%) 358 (0.86%) <.01 1,183 (9.35%) 1,535 (3.71%) <.01 2,139 (16.90%) 4,244 (10.25%) <.01
Decubitus Ulcer 803 (21.12%) 172 (7.16%) <.01 1,429 (37.59%) 393 (16.35%) <.01 1,116 (29.35%) 861 (35.83%) <.01
Surgical site infection & Device or Graft 123 (1.65%) 137 (0.51%) <.01 598 (8.04%) 1,812 (6.73%) <.01 2,747 (36.93%) 6,752 (25.06%) <.01
Folliculitis, Impetigo, Furuncle, Mastitis & Other SSTIs 76 (6.46%) 62 (1.18%) <.01 115 (9.78%) 217 (4.13%) <.01 189 (16.07%) 510 (9.70%) <.01
All SSTIs in subgroup 1,671 (6.66%) 729 (0.96%) <.01 3,325 (13.26%) 3,957 (5.21%) <.01 6,191 (24.69%) 12,367 (16.27%) <.01
a

Complications are not mutually exclusive.